Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134901

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134280

Published: 2020

Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134179

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Regis Peffault De Latour, MD PhD, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath, Mohamed Hamdani, MS, Temitayo Ajayi, Hisakazu Nishimori, MD PhD, Ilene C. Weitz

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-141061

Published: 2020

Journal Articles

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Louise Arnold, Richard Kelly, BSc, MD, Talha Munir, MBBS, Petra Muus, MD PhD, Alexandra Pike, MBBS, Kathryn Riley, Briony Forrest, Jeanifer Gachev, Morag Griffin, MBChB, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141769

Published: 2020

Journal Articles

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R Brown, MD PhD, John C. Byrd, MD, Paolo Ghia, MD PhD, Jeff P Sharman, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Deborah M. Stephens, DO, Clare Sun, MD, Wojciech Jurczak, John M. Pagel, MDPhD, Alessandra Ferrajoli, MD, Priti Patel, MD, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, MD, Javid J. Moslehi, MD, Richard R. Furman, MD

Blood (2020) 136 (Supplement 1): 52–54.

https://doi.org/10.1182/blood-2020-134797

Published: 2020

Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141279

Published: 2020

Journal Articles

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Rachael Jones, BSc, Petra Muus, MD PhD, Talha Munir, MBBS, Alexandra Pike, MBBS, Louise Arnold, Jeanifer Gachev, Briony Forrest, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140256

Published: 2020

Journal Articles

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Louise Arnold, Ray Borrow, PhD FRCPath, Kathryn Riley, Talha Munir, MBBS, Richard Kelly, BSc, MD, Rachael Jones, BSc, Jeanifer Gachev, Briony Forrest, Alexandra Pike, MBBS, Petra Muus, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141780

Published: 2020

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136109

Published: 2020

Journal Articles

Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab

Darren J Newton, PhD, Claire E McKinley, BSc, Alonso Ricardo, PhD, Michelle D Hoarty, PhD, Louise Arnold, Kathryn Riley, Nicola Copeland, Talha Munir, Morag Griffin, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3484.

https://doi.org/10.1182/blood.V130.Suppl_1.3484.3484

Published: 2017

Journal Articles

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alexander Roeth, MD, David J. Araten, MD, Yuzuru Kanakura, MD PhD, Loree Larratt, MD FRCP(C), Jamile M. Shammo, MD FASCP, FACP, Amanda Wilson, MPH, PhD, Gilda Shayan, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3488.

https://doi.org/10.1182/blood.V130.Suppl_1.3488.3488

Published: 2017

Journal Articles

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Claire E McKinley, BSc, Stephen John Richards, PhD FRCPath, Talha Munir, Morag Griffin, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Louise Arnold, Kathryn Riley, Nicola Copeland, Darren J Newton, PhD, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3471.

https://doi.org/10.1182/blood.V130.Suppl_1.3471.3471

Published: 2017

Journal Articles

Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria

Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Louise Arnold, Nicola Copeland, Kathryn Riley, Stephen John Richards, PhD FRCPath, Anita Hill, MBChB (Hons), PhD

Blood (2017) 130 (Supplement 1): 1175.

https://doi.org/10.1182/blood.V130.Suppl_1.1175.1175

Published: 2017

Journal Articles

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 56.

https://doi.org/10.1182/blood.V130.Suppl_1.56.56

Published: 2017

Journal Articles

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Fraser Macrae, BSc, PhD, Polly Bowman, Emma Linton, Barnaby Peacock-Young, Deborah Clarke, MSc, Darren J Newton, PhD, Claire E McKinley, BSc, Kathryn Riley, Nicola Copeland, Louise Arnold, Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Stephen John Richards, PhD FRCPath, Robert Ariens, BSc, PhD, Anita Hill, MBChB (Hons), PhD

Blood (2017) 130 (Supplement 1): 462.

https://doi.org/10.1182/blood.V130.Suppl_1.462.462

Published: 2017

Journal Articles

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Veronika Opatrna, MD, Eugen Tausch, MD, Graeme Fraser, MD, Anne-Sophie Michallet, MD PhD, Peter Hillmen, MBChB, PhD, Jan Dürig, MD, Matt Kalaycio, MD, John G. Gribben, MDDSc FMedSci, Thomas J. Kipps, MD, Brendan Purse, Jennie Zhang, Sabine De Bedout, Asher A. Chanan-Khan, MD, Michael J. Hallek, MD, Clemens-Martin Wendtner, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 4311.

https://doi.org/10.1182/blood.V130.Suppl_1.4311.4311

Published: 2017

NARROW

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only